Smoking and tardive dyskinesia in male patients with chronic schizophrenia. 2011

Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA. xyzhang@bcm.edu

Interactions between smoking and movement disorders include the contrasting associations of more cigarette smoking with reductions in Parkinson's disease and increases in tardive dyskinesia (TD) symptoms. Here we examine the relationship between smoking and TD in a large sample of inpatients with schizophrenia. We used cross-sectional naturalistic methods to analyze the prevalence and severity of neuroleptic-induced TD in relation to cigarette smoking among 764 male chronic and medicated inpatients meeting DSM-IV criteria for schizophrenia. We administered a detailed questionnaire including general information, medical and psychological conditions, and smoking behaviors. We evaluated TD severity using the abnormal involuntary movement scale (AIMS) and psychopathology using the Positive and Negative Syndrome Scale (PANSS). The main statistical analyses used cross-tabulations for the prevalence of TD by smoking and multivariate regression analyses for continuous measures (AIMS and PANSS). We found that the prevalence of TD did not significantly differ between smokers (41%=237/578) and non-smokers (37%=69/186). Secondary outcomes showed a significant association between the AIMS total score and age, duration of illness and hospitalization times. Thus, smoking was not associated with TD in male Chinese schizophrenics, but consistent with previous reports, older patients with a longer duration of illness and more hospitalizations showed greater severity of TD.

UI MeSH Term Description Entries
D007297 Inpatients Persons admitted to health facilities which provide board and room, for the purpose of observation, care, diagnosis or treatment. Inpatient
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
March 2011, The Journal of clinical psychiatry,
Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
September 2003, Progress in neuro-psychopharmacology & biological psychiatry,
Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
July 1988, Biological psychiatry,
Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
October 1987, Biological psychiatry,
Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
July 2013, The British journal of psychiatry : the journal of mental science,
Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
January 2003, The pharmacogenomics journal,
Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
June 1992, Biological psychiatry,
Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
November 1989, The British journal of psychiatry. Supplement,
Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
December 2018, International journal of methods in psychiatric research,
Xiang Yang Zhang, and Ya Qin Yu, and Shilong Sun, and Xuan Zhang, and Wenjun Li, and Mei Hong Xiu, and Da Chun Chen, and Fu De Yang, and Fengyan Zhu, and Therese A Kosten, and Thomas R Kosten
February 2009, Journal of clinical psychopharmacology,
Copied contents to your clipboard!